Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06329492 · ClinicalTrials.gov registry record · Phase 1

Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis

A Phase 1 study of Osteoarthritis and Knee Osteoarthritis, sponsored by Mayo Clinic.

Completed
Registry status
Phase 1
Development phase
20
Enrollment target
1
Study location

NCT06329492 is a Phase 1 study of Osteoarthritis and Knee Osteoarthritis that has completed, run by Mayo Clinic. The registered enrollment target is 20 participants, below the 818-participant average among 135 other Osteoarthritis trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06329492, a Phase 1 study of Osteoarthritis and Knee Osteoarthritis, has completed, sponsored by Mayo Clinic.

COMPLETED
Registry status
Phase 1
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine the effectiveness and safety of autologous alpha-2 macroglobulin rich plasma (A2MRP) injections in the treatment of knee osteoarthritis (OA).

Interventions

  • BIOLOGICAL Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP)

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2024-01-09
Est. Completion 2026-02-06
Phase Phase 1

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT06329492

The ClinicalTrials.gov registry entry for NCT06329492 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 818-participant average among 135 other Osteoarthritis trials with a reported enrollment target (98% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Osteoarthritis appearing as the primary indexed condition, and to 1 intervention - of which Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) is the first listed.

NCT06329492 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT06329492 about?

NCT06329492 is a clinical study titled "Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis". The purpose of this study is to determine the effectiveness and safety of autologous alpha-2 macroglobulin rich plasma (A2MRP) injections in the treatment of knee osteoarthritis (OA).

What is the current status of trial NCT06329492?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2024-01-09. Estimated completion is 2026-02-06.

What conditions does trial NCT06329492 study?

This clinical trial studies the following conditions: Osteoarthritis, Knee Osteoarthritis, OA.

What interventions are being tested in trial NCT06329492?

The interventions under investigation include: Autologous Alpha-2 Macroglobulin Rich Plasma (A2MRP) (BIOLOGICAL).

Who is sponsoring clinical trial NCT06329492?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06329492 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.